Top 20 Drug Companies in the US by Revenue
Following the Covid-19 pandemic, which drastically altered the way of living, the top pharmaceutical or drug companies in the world became the center of attention for people everywhere due to the spike...
Biomarin Pharmaceutical Inc (BMRN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Viking Global Andreas Halvorsen | 4,215,456 | $372,983,547 | +2% | 1.51% |
| 2. | VenBio Select Advisor Kurt Von Emster | 3,850,000 | $340,648,000 | -4% | 5.31% |
| 3. | Baker Bros. Advisors Julian Baker And Felix Baker | 3,810,248 | $337,130,743 | 1.94% | |
| 4. | Palo Alto Investors William Leland Edwards | 1,831,035 | $162,009,977 | 15.32% | |
| 5. | OrbiMed Advisors Samuel Isaly | 1,615,210 | $142,913,781 | 3.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $86.75 | 3,625 | Director | 10,905 | 2022-10-31 | Filing | |
| $78.84 | 900 | Director | 30,740 | 2020-08-31 | Filing | |
| $78.22 | 11,900 | Director | 29,840 | 2020-08-31 | Filing | |
| $21.76 | 161 | Officer | 100,574 | 2012-10-31 | Filing | |
| $21.76 | 548 | Officer | 15,294 | 2012-10-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $90.00 | 5,000 | Officer | 60,804 | 2023-08-16 | Filing | |
| $90.43 | 12,000 | Officer | 176,187 | 2023-08-10 | Filing | |
| $93.30 | 5,360 | Officer | 40,041 | 2023-08-09 | Filing | |
| $89.42 | 11,000 | Officer | 69,474 | 2023-08-08 | Filing | |
| $88.29 | 6,000 | Officer, Director | 422,732 | 2023-08-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,406,539 | $1,628,610,571 | 1.37% | |
| 2. | 17,701,210 | $1,566,203,061 | 0.03% | |
| 3. | 14,607,187 | $1,292,443,904 | 0.03% | |
| 4. | 14,153,503 | $1,252,301,945 | 0.84% | |
| 5. | 6,458,729 | $571,468,342 | 0.03% |
News See All
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2023 Earnings Call Transcript
Operator: Hello and welcome to the BioMarin Pharmaceutical Third Quarter 2023 Conference Call. All lines have been placed on meet to prevent any background noise.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2023 Earnings Call Transcript
Traci McCarty: Thank you, Katie, and thank you, everyone for joining us today.
Analysts Are Cutting Price Targets of These 5 Stocks
In this article, we discuss the 5 stocks receiving price-target cut from analysts.
10 Martin Shkreli Stock Picks and Their Performance
Martin Shkreli a.k.a. "Pharma Bro" is known for a variety of reasons, many of which are tinged with notoriety.
14 Best Biotech Stocks To Buy According To Hedge Funds
Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, and biotechnology, are making rapid leaps forward.
Here’s Why You Should Invest in BioMarin Pharmaceutical (BMRN)
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” first quarter 2023 investor letter. A copy of the same can be downloaded here.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2023 Earnings Call Transcript
Operator: Welcome to the BioMarin Pharmaceuticals First Quarter Investor Update Call. Hosting the conference call today from BioMarin is Traci McCarty, Group Vice President, Investor Relations.
Is BioMarin Pharmaceutical (BMRN) an Attractive Investment?
ClearBridge Investments, an investment management company, released its “ClearBridge Sustainability Leaders Strategy” fourth 2022 investor letter. A copy of the same can be downloaded here.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2022 Earnings Call Transcript
Operator: Welcome to the BioMarin Fourth Quarter Investor Update Call. Hosting the conference call today from BioMarin is Traci McCarty, Group Vice President of Investor Relations.
Billionaire Hedge Funds
